webinar register page

CANOSC - Rehabilitation of chronic post-stroke spastic paresis: impact of guided self-rehabilitation contracts on gait at the Cardinal Paul Emile LEGER National Center for Rehabilitation
*Delivered in French with simultaneous translation to English*
Log into the webinar, click the language you would like to hear. To hear the interpreted language only, click Mute Original Audio.

Stroke is a major cause of spastic paresis. We conducted a randomized controlled trial. The intervention arm performed GSRC and the control arm underwent Conventional Rehabilitation sessions. Initial and final assessments took place ten weeks apart. Outcome measures included 10 meters walking test at comfortable and fast speed, passive range of motion (XV1), angle of catch (XV3, Tardieu) and active range of motion (XA). We used Student T test and Mann Whitney test for statistical analysis. At the end of intervention, participants undergoing GSRC presented greater improvement of comfortable and fast walking speed about 40% and 11%, respectively. Compared with controls, the intervention group reported higher reduction of coefficient of shortening with a significant difference between the two arms (p=0,047).
GSRC improved soft tissue contracture and walking speed more than Conventional Rehabilitation in patients with chronic post stroke spastic paresis.

At the end of the session, participants will be able to:
1 - evaluate the impact of Guided Self-Rehabilitation Contracts (GSRC) on gait of patients with chronic post stroke spastic paresis.

Award recipient speakers:
Sinforian Kambou, Institute of Applied Neurosciences and Functional Rehabilitation
Michael Temgoua, Bethesda Hospital of Yaoundé

Hosts:
Rajiv Reebye
Paul Winston
Mary Ann Keenan

CanMEDS Roles: Medical Expert

This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada, and approved by the CAPMR. You may claim a maximum of 1.0 hour.

This webinar was co-developed with Allergan and CANOSC and was planned to achieve scientific integrity, objectivity and balance.

01:37:00

* Required information
Loading